AU2007270931A1 - Fused pyrimido compounds - Google Patents

Fused pyrimido compounds Download PDF

Info

Publication number
AU2007270931A1
AU2007270931A1 AU2007270931A AU2007270931A AU2007270931A1 AU 2007270931 A1 AU2007270931 A1 AU 2007270931A1 AU 2007270931 A AU2007270931 A AU 2007270931A AU 2007270931 A AU2007270931 A AU 2007270931A AU 2007270931 A1 AU2007270931 A1 AU 2007270931A1
Authority
AU
Australia
Prior art keywords
optionally substituted
group
alkyl
optionally
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007270931A
Other languages
English (en)
Inventor
Christopher Thomas Halsall
David Alan Rudge
Iain Simpson
Richard Andrew Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2007270931A1 publication Critical patent/AU2007270931A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
AU2007270931A 2006-07-06 2007-07-05 Fused pyrimido compounds Abandoned AU2007270931A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81887806P 2006-07-06 2006-07-06
US60/818,878 2006-07-06
PCT/GB2007/002490 WO2008003958A2 (en) 2006-07-06 2007-07-05 Fused pyrimido compounds

Publications (1)

Publication Number Publication Date
AU2007270931A1 true AU2007270931A1 (en) 2008-01-10

Family

ID=38857945

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007270931A Abandoned AU2007270931A1 (en) 2006-07-06 2007-07-05 Fused pyrimido compounds

Country Status (19)

Country Link
US (1) US7709471B2 (enExample)
EP (1) EP2046793A2 (enExample)
JP (1) JP2009542613A (enExample)
KR (1) KR20090038895A (enExample)
CN (1) CN101511836A (enExample)
AR (1) AR061850A1 (enExample)
AU (1) AU2007270931A1 (enExample)
BR (1) BRPI0714045A2 (enExample)
CA (1) CA2656936A1 (enExample)
CL (1) CL2007001973A1 (enExample)
EC (1) ECSP099044A (enExample)
IL (1) IL196207A0 (enExample)
MX (1) MX2009000220A (enExample)
NO (1) NO20090052L (enExample)
RU (1) RU2009103810A (enExample)
TW (1) TW200808325A (enExample)
UY (1) UY30472A1 (enExample)
WO (1) WO2008003958A2 (enExample)
ZA (1) ZA200900073B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008006025A1 (en) 2006-07-06 2008-01-10 Array Biopharma Inc. Dihydrofuro pyrimidines as akt protein kinase inhibitors
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
DK2049500T3 (da) 2006-07-06 2011-12-12 Array Biopharma Inc Cyclopenta [d]-pyrimidiner som AKT-proteinkinase-inhibitorer
SI2054418T1 (sl) 2006-07-06 2012-02-29 Array Biopharma Inc Dihidrotieno pirimidini kot AKT protein kinazni inhibitorji
PT2139892E (pt) * 2007-03-22 2011-11-21 Takeda Pharmaceutical Pirimidodiazepinas substituídas úteis como inibidores da plk1
KR20150091196A (ko) 2007-07-05 2015-08-07 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
EP2190849B1 (en) * 2007-08-15 2013-11-20 Vertex Pharmceuticals Incorporated 4-(9-(3,3-difluorocyclopentyl)-5,7,7-trimethyl-6-oxo-6,7,8,9-tetrahydro-5h-pyrimido[4,5-b[1,4]diazepin-2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases plk1 to plk4 for the treatment of proliferative diseases
NZ584760A (en) * 2007-09-25 2012-03-30 Takeda Pharmaceutical Polo-like kinase inhibitors
EP2610256B1 (en) * 2007-09-28 2016-04-27 Cyclacel Limited Pyrimidine derivatives as protein kinase inhibitors
US20090291938A1 (en) * 2007-11-19 2009-11-26 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
KR101624752B1 (ko) 2008-01-09 2016-05-26 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 저해물질로써의 수산화된 피리미딜 시클로펜탄
CA2711699A1 (en) 2008-01-09 2009-07-16 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
EP2303889A1 (en) 2008-06-18 2011-04-06 F. Hoffmann-La Roche AG Halo-substituted pyrimidodiazepines as plkl inhibitors
AU2009322346B2 (en) * 2008-12-03 2015-07-02 The Scripps Research Institute Stem cell cultures
EP2379559B1 (en) 2009-01-06 2017-10-25 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
GEP20207129B (en) 2009-06-17 2020-07-10 Vertex Pharma Inhibitors of influenza viruses replication
TWI399551B (zh) * 2009-06-26 2013-06-21 Senao Networks Inc Burner device and burner method
AU2010299579A1 (en) * 2009-09-25 2012-05-03 Vertex Pharmaceuticals Incorporated Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
NZ599342A (en) * 2009-09-25 2014-04-30 Vertex Pharma Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
US8466155B2 (en) 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
US20110218295A1 (en) * 2010-03-02 2011-09-08 Basf Se Anionic associative rheology modifiers
US8673275B2 (en) 2010-03-02 2014-03-18 Basf Se Block copolymers and their use
CN103492381A (zh) 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
WO2012135759A1 (en) 2011-04-01 2012-10-04 Genentech, Inc. Combinations of akt inhibitor compounds and abiraterone, and methods of use
CN103841976A (zh) 2011-04-01 2014-06-04 基因泰克公司 Akt和mek抑制剂化合物的组合及其使用方法
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
GB201205752D0 (en) * 2012-03-30 2012-05-16 Cyclacel Ltd Treatment
EP3421468B1 (en) 2013-11-13 2020-11-04 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
HRP20191525T1 (hr) 2013-11-13 2019-11-29 Vertex Pharma Inhibitori replikacije virusa influence
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
JP6704416B2 (ja) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤を調製する方法
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
US10112948B2 (en) 2015-07-06 2018-10-30 The Board Of Regents Of The University Of Texas System Benzamide or benzamine compounds useful as anticancer agents for the treatment of human cancers
AU2017248186B2 (en) * 2016-04-07 2021-10-21 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating PI3K-mediated disorders
EP4110464A1 (en) * 2020-02-28 2023-01-04 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2022145989A1 (ko) * 2020-12-31 2022-07-07 (주) 업테라 선택적 plk1 억제제로서의 피리미도디아제핀 유도체
CA3228601A1 (en) * 2021-08-10 2023-02-16 Soo Hee RYU Novel plk1 degradation inducing compound
KR20240096913A (ko) * 2021-08-30 2024-06-26 레믹스 테라퓨틱스 인크. 스플라이싱 조절을 위한 화합물 및 방법
CN113999244B (zh) * 2021-12-30 2022-05-20 北京鑫开元医药科技有限公司 一种4H-吡喃并[2,3-c]吡啶-4-酮类化合物及其制备方法
CN114392258B (zh) * 2021-12-30 2024-04-16 北京朗瑞邦科技有限公司 一种4H-吡喃并[2,3-c]吡啶-4-酮类化合物药物制剂及其制备方法
TW202345806A (zh) 2022-03-31 2023-12-01 美商艾伯維有限公司 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ531928A (en) 2001-09-04 2005-10-28 Boehringer Ingelheim Pharma Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
US6806272B2 (en) 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
MXPA05009068A (es) 2003-02-26 2005-10-19 Boehringer Ingelheim Pharma Dihidro-pteridinonas, metodo para la produccion y uso del mismo en la forma de farmacos.
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004034623A1 (de) 2004-07-16 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 6-Formyl-tetrahydropteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
EP1632493A1 (de) 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
WO2006021547A1 (de) 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinone als plk (polo like kinase) inhibitoren
JP2008510771A (ja) 2004-08-27 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノン、その製造方法および医薬薬剤としてのその使用
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
KR20080095902A (ko) * 2006-02-14 2008-10-29 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제의 억제제로서 유용한 디하이드로디아제핀

Also Published As

Publication number Publication date
AR061850A1 (es) 2008-09-24
CN101511836A (zh) 2009-08-19
WO2008003958A2 (en) 2008-01-10
TW200808325A (en) 2008-02-16
US7709471B2 (en) 2010-05-04
BRPI0714045A2 (pt) 2012-12-11
WO2008003958A3 (en) 2008-03-06
ZA200900073B (en) 2010-06-30
RU2009103810A (ru) 2010-08-20
MX2009000220A (es) 2009-01-22
NO20090052L (no) 2009-01-28
KR20090038895A (ko) 2009-04-21
UY30472A1 (es) 2008-02-29
CL2007001973A1 (es) 2008-04-04
ECSP099044A (es) 2009-02-27
JP2009542613A (ja) 2009-12-03
US20080009482A1 (en) 2008-01-10
EP2046793A2 (en) 2009-04-15
CA2656936A1 (en) 2008-01-10
IL196207A0 (en) 2009-09-22

Similar Documents

Publication Publication Date Title
US7709471B2 (en) Compounds
AU2010271270B2 (en) Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
JP7654031B2 (ja) 炎症性障害の治療のための新規化合物及びその医薬組成物
KR102405462B1 (ko) Wee-1 카이네이즈 억제제로 유용한 피리미도피리미디논
EP3596073B1 (en) Tricyclic compounds for use in treatment of proliferative disorders.
EP3596061A1 (en) Compounds useful in the treatment or prevention of a prmt5-mediated disorder
JP2011510010A (ja) ３Ｈ−［１，２，３］トリアゾロ［４，５−ｄ］ピリミジン化合物、ｍＴＯＲキナーゼおよびＰＩ３キナーゼ阻害剤としてのそれらの使用、ならびにそれらの合成
WO2008009909A1 (en) Pteridimones as modulators of polo-like kinase
US20090312336A1 (en) Dihydropteridine compounds as anti proliferative agents
WO2008040951A1 (en) Compounds
WO2021084266A1 (en) Bicyclic nitrogen containing heterocycles as inhibitors of salt-inuced kinase sik2
WO2019145718A1 (en) Compounds
RU2785126C2 (ru) Новые соединения и их фармацевтические композиции для лечения воспалительных заболеваний
EP4612148A1 (en) 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one and 7-amino-1-pyrimido[4,5-d]pyrimidin-2(1 h)-one derivatives as egfr inhibitors for the treatment of cancer
AU2015201984A1 (en) SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted